JP2002509692A5 - - Google Patents

Download PDF

Info

Publication number
JP2002509692A5
JP2002509692A5 JP2000510858A JP2000510858A JP2002509692A5 JP 2002509692 A5 JP2002509692 A5 JP 2002509692A5 JP 2000510858 A JP2000510858 A JP 2000510858A JP 2000510858 A JP2000510858 A JP 2000510858A JP 2002509692 A5 JP2002509692 A5 JP 2002509692A5
Authority
JP
Japan
Prior art keywords
therapeutic composition
seq
analog
composition according
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000510858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002509692A (ja
Filing date
Publication date
Priority claimed from US08/929,140 external-priority patent/US6084090A/en
Application filed filed Critical
Publication of JP2002509692A publication Critical patent/JP2002509692A/ja
Publication of JP2002509692A5 publication Critical patent/JP2002509692A5/ja
Withdrawn legal-status Critical Current

Links

JP2000510858A 1997-09-05 1998-09-03 アンチセンスオリゴヌクレオチドによるヒト乳頭腫ウイルスの阻害 Withdrawn JP2002509692A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/929,140 1997-09-05
US08/929,140 US6084090A (en) 1997-09-05 1997-09-05 Human papilloma virus anti-sense oligonucleotides
PCT/US1998/018320 WO1999013071A1 (en) 1997-09-05 1998-09-03 Human papilloma virus inhibition by anti-sense oligonucleotides

Publications (2)

Publication Number Publication Date
JP2002509692A JP2002509692A (ja) 2002-04-02
JP2002509692A5 true JP2002509692A5 (enExample) 2006-01-05

Family

ID=25457385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000510858A Withdrawn JP2002509692A (ja) 1997-09-05 1998-09-03 アンチセンスオリゴヌクレオチドによるヒト乳頭腫ウイルスの阻害

Country Status (7)

Country Link
US (2) US6084090A (enExample)
EP (2) EP1595954A1 (enExample)
JP (1) JP2002509692A (enExample)
KR (1) KR100604218B1 (enExample)
AU (1) AU9218398A (enExample)
CA (1) CA2302148A1 (enExample)
WO (1) WO1999013071A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541822A (ja) * 1999-04-14 2002-12-10 エム ユー エス シー ファンデーション フォー リサーチ ディベロップメント 組織特異的および病原体特異的毒性物質ならびにリボザイム
US20040209263A1 (en) * 2000-12-07 2004-10-21 Clawson Gary A. Selection of catalytic nucleic acids targeted to infectious agents
DE10154831A1 (de) * 2001-11-08 2003-06-05 Deutsches Krebsforsch PNA-Konjugat oder PNA-Konjugat-Gemisch zur Therapie von mit HPV in Zusammenhang stehenden Erkrankungen
CA2491034A1 (en) * 2002-06-26 2004-01-08 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
US20040248085A1 (en) * 2002-11-29 2004-12-09 Sang-Wha Lee General primers and process for detecting diverse genotypes of human papillomavirus by PCR
GB0500999D0 (en) * 2005-01-18 2005-02-23 Glaxosmithkline Biolog Sa Detection method and materials therefor
KR101197627B1 (ko) 2010-01-18 2012-11-07 (주)레퍼런스바이오랩 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
KR102129852B1 (ko) * 2016-10-11 2020-07-24 주식회사 인코드젠 Rna 간섭 유도 핵산 및 이를 포함하는 hpv 감염 유발 암의 치료용 약학 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457189A (en) * 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
NZ277616A (en) * 1993-11-16 1997-12-19 Genta Inc Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphate internucleosidyl linkages
US5580967A (en) * 1994-05-13 1996-12-03 The Scripps Research Institute Optimized catalytic DNA-cleaving ribozymes
US5683902A (en) * 1994-05-13 1997-11-04 Northern Illinois University Human papilloma virus inhibition by a hairpin ribozyme
US6509149B2 (en) * 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides

Similar Documents

Publication Publication Date Title
Zhao et al. Effect of different chemically modified oligodeoxynucleotides on immune stimulation
EP0928335B1 (en) METHOD FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES
Agrawal Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides
Agrawal et al. Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo
Cohen Antisense oligodeoxynucleotides as antiviral agents
JPH11511014A (ja) 免疫刺激応答が低減した遺伝子発現の調節法
CA2397590A1 (en) Antisense inhibition of ptp1b expression
CA2677176A1 (en) Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
CA2266748A1 (en) Three component chimeric antisense oligonucleotides
CA2229811A1 (en) Inverted chimeric and hybrid oligonucleotides
CA2343102A1 (en) Antisense modulation of survivin expression
JP2003523739A5 (enExample)
IL144975A0 (en) A composition containing an antisense oligonucleotide
EP1100894A2 (en) Short oligonucleotides for the inhibition of vegf expression
JP2021510511A5 (enExample)
US20030036516A1 (en) Method for using oligonucleotides having modified cpg dinucleotides
CA2389036A1 (en) Antisense modulation of integrin-linked kinase expression
IL146565A0 (en) A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5
AU744417B2 (en) Modified antisense nucleotides complementary to a section of the human Ha-Ras gene
CA2495298A1 (en) Use of antisense oligonucleotides to inhibit the expression of akt-1
EP1102842A2 (en) Antisense oligonucleotides for the inhibition of vegf expression
KR100604218B1 (ko) 안티센스 올리고뉴클레오티드에 의한 사람의유두종바이러스의 억제
WO2001061030A3 (en) LIBRARIES OF OPTIMUM SUBSEQUENCE REGIONS OF mRNA AND GENOMIC DNA FOR CONTROL OF GENE EXPRESSION
JP2002526072A (ja) 遺伝子発現の調節のためのヘアピンハイブリダイザー分子
AU646643B2 (en) Antisense oligonucleotides to C-ABL proto-oncogene